Skip to main content

Table 2 Costs, QALY and net monetary benefit results from base case 4-year time horizon

From: Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis

  Combination therapy 5-ARI α-blockers FT
Price $14,000 Price $5000
Costs per patient ($) 1308.58 1566.35 1431.41 14,831.46 5864.82
QALY per patient 1.87 1.87 1.87 1.96 1.96
Willingness-to-pay threshold at $150,000      
Net Monetary Benefit (NMB) ($) 279,191.42 278,633.65 279,068.59 279,168.54 288,135.18
Willingness-to-pay threshold at $50,000      
Net Monetary Benefit (NMB) ($) 92,191.42 91,833.65 92,068.59 83,168.54 92,135.18
  1. QALY Quality-adjusted life years, 5-ARI 5-α-Reductase inhibitors, FT Fexapotide triflutate